New drug option opens for Hard-to-Treat cancers
NCT ID NCT05974410
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, 37 patients have received the drug, and side effects have been mostly mild, such as itching during infusion and brief insomnia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can a new tracer light up hidden prostate cancer?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a personalized exercise program boost recovery in cancer survivors?